7,600 Corcept Therapeutics Incorporated $CORT Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al trimmed its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 28.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 18,974 shares of the biotechnology company’s stock after selling 7,600 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Corcept Therapeutics were worth $2,186,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Parcion Private Wealth LLC acquired a new position in Corcept Therapeutics in the third quarter worth about $420,000. Choreo LLC lifted its stake in Corcept Therapeutics by 8.0% during the third quarter. Choreo LLC now owns 4,190 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 312 shares during the period. Motley Fool Asset Management LLC bought a new position in Corcept Therapeutics during the third quarter worth about $403,000. Brucke Financial Inc. acquired a new stake in Corcept Therapeutics during the third quarter valued at approximately $240,000. Finally, Signaturefd LLC boosted its holdings in Corcept Therapeutics by 30.6% during the third quarter. Signaturefd LLC now owns 1,375 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 322 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported Q3 revenue of about $340.5 million, above the roughly $336.4 million consensus, and earnings of $1.01 per share, beating the $0.79 estimate cited in the results coverage. Earnings were also up from $0.16 per share a year earlier. The revenue and earnings beats are positive signals for the business. Corcept’s Q3 2026 beats on revenue
• Neutral Sentiment: The company also announced its third-quarter financial results and provided a corporate update; the available coverage does not specify additional details from that update that would clearly change the investment outlook. Corcept Announces Third Quarter Results and Corporate Update
• Negative Sentiment: Despite the earnings beat, one report said CORT shares sold off. The coverage does not identify a specific cause, suggesting the strong results were not enough to satisfy investor expectations or overcome other market concerns. Q3 Earnings Beat, Shares Still Sold Off

Corcept Therapeutics Stock Up 1.8%

NASDAQ:CORT opened at $81.93 on Wednesday. The firm has a market cap of $8.86 billion, a PE ratio of 191.57 and a beta of 0.54. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38. The company’s 50-day moving average price is $110.31 and its two-hundred day moving average price is $75.06.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.22. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm had revenue of $340.47 million for the quarter, compared to analysts’ expectations of $336.37 million. During the same period in the prior year, the firm earned $0.16 earnings per share. The company’s quarterly revenue was up 64.0% compared to the same quarter last year. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.83 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Roberto Vieira sold 58,333 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08. Following the sale, the insider directly owned 4,242 shares in the company, valued at $469,843.92. This represents a 93.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David Mahoney sold 103,606 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $118.25, for a total value of $12,251,409.50. Following the sale, the director directly owned 1,133,539 shares of the company’s stock, valued at $134,040,986.75. This represents a 8.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 349,203 shares of company stock worth $40,686,076 over the last ninety days. 20.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CORT shares. Zacks Research lowered Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. HC Wainwright restated a “buy” rating and set a $165.00 target price on shares of Corcept Therapeutics in a research report on Friday, September 18th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.